分子靶向药物相关间质性肺病的现状

The actuality of molecular targeted drugs related interstitial lung disease

近年来分子靶向药物越来越多地用于肿瘤治疗，疗效确切，选择性高，不良反应较少。间质性肺病是其少见不良反应，但症状严重、预后差、致死率高，越来越引起人们的重视。本文就分子靶向药物相关间质性肺病的发病、临床表现、发病机制、处理和治疗作一介绍，以提高临床工作者对分子靶向药物相关间质性肺病的警惕和认识。

In recent years, molecular targeted drugs （MTD） were increasingly used in cancer treatment with the exact curative effect, high selectivity and less adverse reaction. Interstitial lung disease （ILD） is a rare adverse reaction, but as to its severe symptoms, poor prognosis and high fatality rate, it had more and more caused the public attention. In this paper, we will introduce the pathogenesis, clinical manifestation, underlying pathogenesis mechanism and therapy about MTD related ILD. In this way, the clinical workers may improve the awarance of the MTD related ILD.